68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

dc.contributor.authorSathekge, Mike Machaba
dc.contributor.authorLengana, Thabo
dc.contributor.authorModiselle, Moshe
dc.contributor.authorVorster, Mariza
dc.contributor.authorZeevaart, Jan Rijn
dc.contributor.authorMaes, Alex
dc.contributor.authorEbenhan, Thomas
dc.contributor.authorVan de Wiele, Christophe
dc.contributor.emailmike.sathekge@up.ac.zaen_ZA
dc.date.accessioned2018-01-12T06:42:49Z
dc.date.available2018-01-12T06:42:49Z
dc.date.issued2017-04
dc.description.abstractBACKGROUND : To report on imaging findings using 68Ga-PSMAHBED- CC PET in a series of 19 breast carcinoma patients. METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS : Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptornegative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p= 0.015). CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.en_ZA
dc.description.departmentNuclear Medicineen_ZA
dc.description.librarianam2018en_ZA
dc.description.sponsorshipDepartment of Nuclear Medicine at University Pretoria and NECSA.en_ZA
dc.description.urihttps://link.springer.com/journal/259en_ZA
dc.identifier.citationSathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6.en_ZA
dc.identifier.issn1619-7070 (print)
dc.identifier.issn1619-7089 (online)
dc.identifier.other10.1007/s00259-016-3563-6
dc.identifier.urihttp://hdl.handle.net/2263/63510
dc.language.isoenen_ZA
dc.publisherSpringeren_ZA
dc.rights© The Author(s) 2016. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/).en_ZA
dc.subject68Ga-PSMAen_ZA
dc.subjectPET/CTen_ZA
dc.subjectBreast canceren_ZA
dc.subjectProstate-specific membrane antigen (PSMA)en_ZA
dc.subjectPositron emission tomography (PET)en_ZA
dc.title68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patientsen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sathekge_68GaPSMAHBEDCC_2017.pdf
Size:
2.29 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: